We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

1 hedge funds and large institutions have $66.7K invested in Pardes Biosciences, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 59 → 1 (-58)

100% less capital invested

Capital invested by funds: $63.9M → $66.7K (-$63.8M)

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 58

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-58
Holders Change %
-98.31%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
58
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
FCMV
Foresite Capital Management V
California
-$19.6M
2
VS
VK Services
California
-$11.1M
3
LCM
Lynx1 Capital Management
Puerto Rico
-$7.06M
4
BCM
BML Capital Management
Indiana
-$6.86M
5
TCM
Tang Capital Management
California
-$3.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
1
Barclays
United Kingdom
$66.7K -$774K -374,782 -92%
FCMV
2
Foresite Capital Management V
California
– -$19.6M -10,811,887 Closed
VS
3
VK Services
California
– -$11.1M -6,151,766 Closed
LCM
4
Lynx1 Capital Management
Puerto Rico
– -$7.06M -3,902,434 Closed
BCM
5
BML Capital Management
Indiana
– -$6.86M -3,791,633 Closed
TCM
6
Tang Capital Management
California
– -$3.52M -1,945,206 Closed
C
7
Chescapmanager
Maryland
– -$3.03M -1,672,379 Closed
Vanguard Group
8
Vanguard Group
Pennsylvania
– -$1.8M -994,997 Closed
Goldman Sachs
9
Goldman Sachs
New York
– -$1.52M -838,362 Closed
ACA
10
Arena Capital Advisors
California
– -$1.5M -826,104 Closed
WSL
11
Western Standard LLC
California
– -$874K -482,874 Closed
BlackRock
12
BlackRock
New York
– -$827K -456,689 Closed
DCM
13
DAFNA Capital Management
California
– -$779K -430,291 Closed
HMC
14
Harvard Management Company
Massachusetts
– -$724K -400,000 Closed
Millennium Management
15
Millennium Management
New York
– -$622K -343,595 Closed
AI
16
Acuitas Investments
Washington
– -$482K -266,061 Closed
TAM
17
Terrapin Asset Management
Florida
– -$443K -244,550 Closed
Geode Capital Management
18
Geode Capital Management
Massachusetts
– -$414K -228,575 Closed
RC
19
RBF Capital
California
– -$272K -150,000 Closed
State Street
20
State Street
Massachusetts
– -$216K -119,320 Closed
Renaissance Technologies
21
Renaissance Technologies
New York
– -$148K -81,689 Closed
CAC
22
Cowen and Company
New York
– -$139K -76,839 Closed
BCM
23
Bridgeway Capital Management
Texas
– -$117K -64,600 Closed
MAM
24
Marquette Asset Management
Minnesota
– -$98.2K -54,278 Closed
IC
25
IEQ Capital
California
– -$90.5K -50,000 Closed
1
2 3

PRDS Hedge Fund Activity: Q3 2023 in Review

1 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q3 2023, worth a combined $66.7K — down 100% from $63.9M a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of PRDS and 0 opened new positions — a net loss of 58 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Foresite Capital Management V, exiting entirely with an estimated $19.6M sold.

  • 1 institutional investor held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q3 2023, down from 59 in Q2 2023.
  • Funds reported $66.7K of Pardes Biosciences, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q3 2023 and 58 closed out, a net change of -58 holders.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q3 2023 was Foresite Capital Management V, an estimated $19.6M sold.

Based on aggregated 13F filings for Q3 2023.